BGNE241018P175000
- 0.81
- 0.000.00%
BeiGene Newsroom
Hong Kong Market Speed Reads | The three major indices surged and then fell back, with the technology index and Hang Seng Index stopping the continuous rise; Electrical utilities stocks rose against the market trend, with CGN Power rising more than 5%.
Network technology stocks performed poorly, Xiaomi Group-W rose by 3.37%, Meituan-W fell by 2.28%; Electrical utility stocks rose, CGN Power increased by 5.24%, Huaneng Power International shares rose by 3.52%; Coal industrial concept stocks performed well, China Qinfa rose by 8.70%, Kinetic Dev increased by 7.35%;
Express News | Star Market Evening Review: The biopharmaceutical sector collectively fell, while the semiconductor sector saw mixed gains and losses.
Hong Kong stock market midday review | Hong Kong stocks continue to rise, the Hang Seng Index rose nearly 1%, temporarily recording its 9th consecutive rise; Xiaomi rose nearly 4%, with its stock price hitting a three-year high; electrical utilities stock
Network technology stocks weakened, Xiaomi Corporation-W up 3.87%, jd.com-SW up 1.95%; Electric power stocks performed well, cgn power up 5.94%, huaneng power up 4.46%; Apple supplier stocks rose, aac tech up 4.75%, byd electronic up 2.62%;
The increase in Middle East capital is also coming! The first Chinese Hong Kong ETF in Saudi Arabia has been approved.
Saudi Capital Market Authority announced that AlBilad Investment Company, a subsidiary of Bank Albilad, plans to establish an ETF investing in stocks in Hong Kong, China. The application has been approved.
BeiGene Announces EGM Record Date for Domicile Shift
Hong Kong stocks surged, with the Hang Seng Index closing up 1.43%; biomedical stocks rallied significantly in the late trading session, with Wuxi Apptec up nearly 12%.
The three main stock indexes in Hong Kong surged in the morning, with a significant increase, and the gains slightly narrowed in the afternoon but overall remained strong. At the close, the Hang Seng Index and the H-share Index rose by more than 1%, while the hang seng tech index increased by 1.43%, surging to 2.5% at one point during the day. All three major indexes continued their upward trend, setting new highs in the recent rebound.
Express News | Hong Kong stock CRO concept stocks soared at the close, what happened?
BeiGene Executive Wu Xiaobin Sells Over $1 Million in Company Stock
BeiGene Initiated at Outperform at JMP Securities on Strength of Brukinsa
JMP Securities Initiates Coverage On BeiGene With Market Outperform Rating, Announces Price Target of $288
BeiGene Analyst Ratings
BeiGene's TEVIMBRA Gains Approval for OSCC in Israel
JMP Securities Initiates BeiGene(BGNE.US) With Buy Rating, Announces Target Price $288
JMP Securities analyst Reni Benjamin initiates coverage on $BeiGene(BGNE.US)$ with a buy rating, and sets the target price at $288.According to TipRanks data, the analyst has a success rate of 32.4%
Reni Benjamin Endorses BeiGene With a Buy Rating Amidst Strong Financial Outlook and Market Penetration
BeiGene Says Israeli Ministry Of Health Approved TEVIMBRA (Tislelizumab) As Monotherapy For Treatment Of Adult Patients With Unresectable Or Metastatic OESCC After Prior Systemic Chemotherapy
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
Hong Kong stocks turned around in the afternoon! Both Hang Seng Index and Technology Index reversed and rose, what happened?
Analysts believe that, under the current circumstances, both the Hong Kong stock market and the A-share market need policies as triggers. If China's stimulus policies can timely follow and exceed expectations after the Fed rate cut, the market may usher in a wave of prosperity.
US stock preview | Earnings guidance exceeds expectations! Oracle continues to rise more than 6% pre-market; Is the US stock correction over? Deutsche Bank: Three major bullish factors may support new highs in US stocks.
The Q4 revenue outlook does not highlight the profitability improvement of AI, and Adobe's pre-market plunge exceeds 8%; Fitch: The Fed's rate cut should be gradual rather than hasty, and is expected to make a moderate 250 basis point rate cut over the next two years; Will the Fed's rate cut signal be sounded? Goldman Sachs executives highly recommend small-cap stock hunting.
Beigene's stock rose nearly 2% pre-market as the National Medical Products Administration accelerated the approval of clinical pharmaceuticals.
On September 13th, Beigene (BGNE.US) rose 1.9% pre-market to $200. The State Council Information Office held a series of themed press conferences on "Promoting High-Quality Development" today. Li Li, the director of the National Medical Products Administration, introduced that the NMPA is accelerating the evaluation and approval of urgently needed clinical products, and will include eligible products in the priority evaluation and approval process. The time limit for the evaluation and approval of innovative drug clinical trials will be shortened from 60 working days to 30 working days.
Hong Kong pharmaceutical stocks continue to rise! The National Medical Products Administration accelerates the approval of clinical drugs, institutions are bullish on the rapid development of innovative drugs.
Soochow Securities has released a research report stating that the development of domestic new drugs in various stages of clinical trials and the participation of domestic new drugs in international multicenter clinical trials reflect a significant enhancement of China's research and development capabilities.